The IGHS Group welcomed, at the Oman International Hospital, the neurotech company REGEnLIFE

The IGHS Group welcomed, at the Oman International Hospital, the neurotech company REGEnLIFE that works at an advanced clinical stage on the treatment of neurodegenerative diseases.

REGEnLIFE and IGHS settled a strategic partnership to anticipate future developments related with the mission of the French company, offering innovative technologies that will improve the health and everyday lives of patients with debilitating neurological conditions such as Alzheimer's disease. 

REGEnLife has as Chief Medical Officer and Chairman of the Scientific Advisory Board the Professor Jacques Touchon, former Dean of the Montpellier School of Medicine and International Key Opinion Leader on Alzheimer’s disease, that was present in Oman.

• OIH Introduces Revolutionary Treatment for Keratoconus: Corneal Allogeneic Intrastromal Ring Implants (CAIRS)

  Oman International Hospital is thrilled to announce the successful introduction of a groundbreaking procedure designed to treat keratoconus: Corneal Allogeneic Intrastromal Ring Implants (CAIRS). This innovative treatment marks a significant advancement in ophthalmology, offering new hope to patients suffering from this debilitating corneal disorder.
   

  Read more
• IGHS celebrates the inauguration of new Insparya Clinic at Oman International Hospital

  With the presence of the distinguished shareholders, Sheika Amal Suhail Bahwan - representing Suhail Bahwan Group, and Mr. Fathi Al Balushi - representing Oman Brunei Investment Company, Insparya announces its strategic partnership with IGHS, inaugurating its new branch at Oman International Hospital.

  Read more